Differential diagnosis of anemia in pregnant women
https://doi.org/10.20538/1682-0363-2017-1-140-151
Abstract
The review is dedicated to the diagnostics of hypochromic microcytic anemia among pregnant women with carbohydrate metabolism disorders by means of existing laboratory algorithm of examination. We give some data on the anemic syndrome in women with diabetes mellitus type 1. These data demonstrate an equal occurrence of anemia of chronic disorder and iron-deficiency anemia in this group of patients. Special attention is paid to the role of hepcidin in iron metabolism as well as to the mechanisms of regulation of hepcidin production under normal and pathological conditions. The review cites researches, which demonstrate the effectiveness of hepcidin measurement for differential diagnostics of anemic syndrome. We also touch upon the problem concerning treatment of anemia of chronic disorder.
About the Authors
T. S. Prokhorenko
Siberian State Medical University
Russian Federation
Russian Federation
PhD, Researcher, Central Research Laboratory,
2, Moskow Trakt, Tomsk, 634050
A. P. Zima
Siberian State Medical University;
Immanuel Kant Baltic Federal University, Kaliningrad, Russian Federation
Russian Federation
Russian Federation
Chief Researcher, Central Research Laboratory, Professor of the Department of Pathophysiology, 2, Moskow Trakt, Tomsk, 634050;
Senior Researcher, Laboratory of Immunology and Cell Biotechnology, 14A, Nevsky Str., Kaliningrad, 236041
T. V. Saprina
Siberian State Medical University
Russian Federation
Russian Federation
DM, Professor of the Department of Endocrinology and Diabetology,
2, Moskow Trakt, Tomsk, 634050
N. N. Musina
Siberian State Medical University
Russian Federation
Russian Federation
Ordinator of the Department of Endocrinology and Diabetology,
2, Moskow Trakt, Tomsk, 634050
N. S. Shakhmanova
Siberian State Medical University
Russian Federation
Russian Federation
Intern in the Department of Biochemistry and Molecular Biology with a Course of Clinical Laboratory Diagnostics,
2, Moskow Trakt, Tomsk, 634050
V. V. Novitsky
Siberian State Medical University
Russian Federation
Russian Federation
DM, Professor, Academician of RAS, Head of the Department of Pathophysiology,
References
1. Nikiforovich I.I., Litvinov А.V., Ivanyan А.N. Rol’ gepsidina v razvitii anemii u beremennykh [The role of hepcidin in the development of anemia in pregnant women] // Rossiyskiy vestnik akushera-ginekologa – Russian Bulletin of Obstetrician-Gynecologist. 2010; 10 (1): 11–14 (in Russian).
2. Repina M.А., Bobrov S.А. Аnemicheskiy sindrom u beremennykh: voprosy patogeneza, diagnoza i lecheniya [Anemic syndrome in pregnancy: pathogenesis issues, diagnosis and treatment] // Zhurnal akusherstva i zhenskikh bolezney – Journal of Obstetrics and Woman Disease. 2010; 2: 3–11 (in Russian).
3. Tsalikhin А.D., Buyevich E.I. Probleme anemii beremennykh [On the problem of pregnant women anemia] // Sibirskiy meditsinskiy zhurnal – Siberian Medical Journal. 2010; (1): 74–76 (in Russian).
4. Saprina T.V., Lazarenko F.E., Prokhorenko T.S., Ryazantseva N.V., Vorozhtsova I.N. Rol’ Th1/Th2 disbalansa immunnogo otveta v determinatsii klinicheskikh osobennostey autoimmunnogo sakharnogo diabeta vzroslykh [The role of Th1/Th2 immune response imbalance determination in clinical features of autoimmune diabetes adult] // Sakharnyy diabet – Diabetes Mellitus. 2011; 14 (2): 12–17. DOI: 10.14341/2072-0351-5628 (in Russian).
5. Saprina T.V., Lazarenko, F.E., Prokhorenko T.S., Ryazantseva N.V., Vorozhtsova I.N. Osobennosti produktsii tsitokinov Th1/Th2-profilya u patsiyentov s razlichnymi klinicheskimi variantami autoimmunnogo sakharnogo diabeta [Features of cytokine production by Th1/Th2-profile in patients with different clinical variants autoimmune diabetes] // Tsitokiny i vospaleniye – Cytokines and Inflammation. 2012; 11 (2): 51–57 (in Russian).
6. Kologrivova I.V., Suslova T.E., Koshel’skaya O.А., Vinnitskaya I.V., ZHuravleva O.А., Nikonova E.S. Funktsionirovaniye effektornykh i regulyatornykh T-limfotsitov pri narushenii tolerantnosti k uglevodam i sakharnom diabete 2-go tipa, assotsiirovannykh s arterial’noy gipertenziyey [Functioning of effector and regulatory T lymphocytes in case of violation of carbohydrate tolerance and type 2 diabetes associated with hypertension] // Tsitokiny i vospaleniye – Cytokines and Inflammation. 2012; 11 (2): 38–43 (in Russian).
7. Kologrivova I.V., Suslova T.E., Koshel’skaya O.А., Vinnitskaya I.V., Trubacheva O.А. Sistema matriksnykh metalloproteinaz i sekretsiya tsitokinov pri sakharnom diabete 2-go tipa i narushenii tolerantnosti k uglevodam, assotsiirovannykh s arterial’noy gipertenziyey [System of matrix metalloproteinases and cytokine secretion in type 2 diabetes mellitus and impaired carbohydrate tolerance associated with arterial hypertension] // Byulleten’ eksperimental’noy biologii i meditsiny – Bulletin of Experimental Biology and Medicine. 2013; 156 (11): 578–581. DOI: 10.1007/s10517-014-2413-4 (in Russian).
8. Kufelkina T.YU., Valeyeva F.V. Аnemiya u bol’nykh sakharnym diabetom 1 tipa [Anemia in patients with type 1 diabetes] // Sakharnyy diabet – Diabetes Mellitus. 2010; 13 (4): 49–53. DOI: 10.14341/2072-0351-6057 (in Russian).
9. Аbakumova А.А., Kufelkina T.YU. Struktura anemicheskogo sindroma u bol’nykh sakharnym diabetom 1 tipa na fone beremennosti [Structure of anemia in patients with type 1 diabetes on a background of pregnancy] // Prakticheskaya meditsina – Practical medicine. 2011; 55 (7): 35–38 (in Russian).
10. ABC of Clinical Haematology / ed. D. Provan. 3rd ed. London: BMJ Books, 2007: 112.
11. Mehta A., Hoffbrand V. Haematology at a Glance. 3rd ed. N.-Y.: Wiley–Blackwell, 2009: 128.
12. Pitkin J., Peattie A., Magowan B. Obstetrics and Gynecology. 1st.ed. Philadelphia: Churchill Livingstone, 2003:172.
13. Huch R., Breymann C. Anaemia in pregnancy and the puerperium. 2nd ed. Bremen: Uni-Med, 2005: 96.
14. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation // Blood. 2003. 102 (3): 783–788.
15. Ryazantseva N.V., Novitskiy V.V., ZHukova O.B., Urazova O.I., Radzivil T.T., Kulagina I.V., Kovaleva N.P. Sovremenny tekhnologii laboratornoy meditsiny [Modern laboratory medicine technology]. Tomsk: Pechatnaya manufaktura Publ., 2008: 360 (in Russian).
16. Dolgov V.V., Lugovskaya S.A., Pochtar’ M.E., Fedorova M.M. Laboratornaya diagnostika narushenii obmena zheleza [Laboratory diagnosis of disorders of iron metabolism]. M-Tver, Izdatel’stvo «Triada» Publ., 2014: 72 (in Russian).
17. Alam F., Fatima F., Orakzai S., Iqbal N., Fatima S.S. Elevated levels of ferritin and hs-CRP in type 2 diabetes // J. Pak. Med. Assoc. 2014; 64 (12): 1389–1391.
18. Huang J., Karnchanasorn R., Ou H.Y., Feng W., Chuang L.M., Chiu K.C., Samoa R. Association of insulin resistance with serum ferritin and aminotransferases-iron hypothesis // World J. Exp. Med. 2015; 5 (4): 232–243. DOI: 10.5493/wjem.v5.i4.232.
19. Huth C., Beuerle S., Zierer A., Heier M., Herder C., Kaiser T., Koenig W., Kronenberg F., Oexle K., Rathmann W., Roden M., Schwab S., Seissler J., Stöckl D., Meisinger C., Peters A., Thorand B. Biomarkers of iron metabolism are independently associated with impaired glucose metabolism and type 2diabetes: the KORA F4 study // Eur. J. Endocrinol. 2015; 173 (5): 643–653. DOI: 10.1530/EJE-15-0631.
20. Liu B.W., Xuan X.M., Liu J.R., Li F.N., Yin F.Z. The Relationship between Serum Ferritin and Insulin Resistance in Different Glucose Metabolism in Nonobese Han Adults // Int. J. Endocrinol. 2015; 642194. DOI: 10.1155/2015/642194.
21. Wei D., Chen T., Li J., Gao Y., Ren Y., Zhang X., Yu H., Tian H. Association of Serum Gamma-Glutamyl Transferase and Ferritin with the Metabolic Syndrome // J. Diabetes. Res. 2015; 741–731. DOI: 10.1155/2015/741731.
22. Pasricha S.R., Drakesmith H. Iron Deficiency Anemia: Problems in Diagnosis and Prevention at the Population Level // Hematol. Oncol. Clin. North. Am. 2016; 30 (2): 309–325. DOI: 10.1016/j.hoc.2015.11.003.
23. Tsvetayeva N.V., Levina А.А., Mamukova YU.I. Osnovy regulyatsii obmena zheleza [Basics of the regulation of iron metabolism] // Klinicheskaya onkogematologiya. Fundamental’nyye issledovaniya i klinicheskaya praktika – Clinical Oncohematology. Basic Research and Clinical Practice. 2010; 3 (3): 278–283 (in Russian).
24. Lukina E.А., Dezhenkova А.V. Metabolizm zheleza v norme i pri patologii. Osnovy regulyatsii obmena zheleza [Iron metabolism in health and disease. Basics of the regulation of iron metabolism] // Klinicheskaya onkogematologiya. Fundamental’nyye issledovaniya i klinicheskaya praktika – Clinical Oncohematology. Basic Research and Clinical Practice. 2015; 8 (4): 355–361 (in Russian).
25. Schaer C.A., Vallelian F., Imhof A., Schoedon G., Schaer D.J. Heme carrier protein (HCP-1) spatially interacts with the CD163 hemoglobin uptake pathway and is a target of inflammatory macrophage activation // J. Leukoc. Biol. 2008; 83 (2): 325–333.
26. Canavesi E., Alfieri C., Pelusi S., Valenti L. Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease // World J. Nephrol. 2012; 1 (6): 166–176. DOI: 10.5527/wjn.v1.i6.166.
27. Deschemin J.C., Vaulont S. Role of hepcidin in the setting of hypoferremia during acute inflammation // PLoS One. 2013; 8 (4): e61050. DOI: 10.1371/journal.pone.0061050.
28. Wilkinson N., Pantopoulos K. The IRP/IRE system in vivo: insights from mouse models // Front Pharmacol. 2014; 5 (176): 00176. DOI: 10.3389/fphar.2014.00176.
29. Fraenkel P.G. Understanding anemia of chronic disease // Hematology Am. Soc. Hematol. Educ. Program. 2015; 1: 14–18. DOI: 10.1182/asheducation-2015.1.14.
30. Li S., Liu Y., Wang Y., Qi P., Wang D. The role of serum hepcidin and ferroportin1 in placenta on iron transfer from mother to fetus // Zhonghua Xue Ye Xue Za Zhi. 2015; 36 (4): 307–311. DOI: 10.3760/cma.j.issn.0253-2727.2015.04.010
31. Martin M.E., Nicolas G., Hetet G., Vaulont S., Grandchamp B., Beaumont C. Transferrin receptor 1 mRNA is downregulated in placenta of hepcidin transgenic embryos // FEBS Lett. 2004; 574 (1-3): 187–191.
32. Ikuta K. Iron dysregulation and anemias // Rinsho Ketsueki. 2015; 56 (10): 1903-1913. DOI: 10.11406/rinketsu.56.1903.
33. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., Ganz T., Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization // Science. 2004; 306 (5704): 2090–2093. DOI: 10.1126/science.1104742.
34. Fleming R.E., Sly W.S. Ferroprotein mutation in autosomal dominant hemochromatosis: loss of function, gain in understanding // J. Clin. Inv. 2001; 108 (4): 521–522. DOI: 10.1172/JCI13739.
35. Weinstein D.A., Roy C.N., Fleming M.D., Loda M.F., Wolfsdorf J.I., Andrews N.C. Inappropriate expression ofhepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease // Blood. 2002; 100 (10): 3776–3781. DOI: 10.1182/blood-2002-04-1260.
36. Nemeth E., Rivera S., Gabajan V., Keller C., Taudorf S., Pedersen B.K., Ganz T. IL-6 mediates hypoferremia inducing the synthesis of the iron regulatory hormone hepcidin // J. Clin. Inv. 2004; 113 (9): 1271–1276. DOI: 10.1172/JCI20945.
37. Rishi G., Wallace D.F., Subramaniam V.N. Hepcidin: regulation of the master iron regulator // Bioscience Reports. 2015; 35 (3): e00192. DOI:10.1042/BSR20150014.
38. Babitt J.L., Huang F.W., Wrighting D.M., Xia Y., Sidis Y., Samad T.A., Campagna J.A., Chung R.T., Schneyer A.L., Woolf C.J., Andrews N.C., Lin H.Y. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression // Nat. Genet. 2006; 38 (5): 531–539.
39. D’Alessio F., Hentze M.W., Muckenthaler M.U. The hemochromatosis proteins HFE, TfR2, and HJV form a membrane-associated protein complex for hepcidin regulation // J. Hepatol. 2012; 57 (5): 1052–1060. DOI: 10.1016/j.jhep.2012.06.015
40. Parrow N.L., Fleming R.E. Bone morphogenetic proteins as regulators of iron metabolism // Annu. Rev. Nutr. 2014; 34: 77–94. DOI: 10.1146/annurev-nutr-071813-105646.
41. Zhao N., Nizzi C.P., Anderson S.A., Wang J., Ueno A., Tsukamoto H., Eisenstein R.S., Enns C.A., Zhang A.S. Low intracellular iron increases the stability of matriptase-2 // J. Biol. Chem. 2015; 290 (7): 4432–4446. DOI: 10.1074/jbc.M114.611913.
42. Ashby D.R., Gale D.P., Busbridge M., Murphy K.G., Duncan N.D., Cairns T.D., Taube D.H., Bloom S.R., Tam F.W., Chapman R., Maxwell P.H., Choi P. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin // Haematologica. 2010; 95 (3): 505–508. DOI: 10.3324/haematol.2009.013136.
43. Kautz L., Jung G., Valore E.V., Rivella S., Nemeth E., Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism // Nat. Genet. 2014; 46 (7): 678–684. DOI: 10.1038/ng.2996.
44. Tanno T., Bhanu N.V., Oneal P.A., Goh S.H., Staker P., Lee Y.T., Moroney J.W., Reed C.H., Luban N.L., Wang R.H., Eling T.E., Childs R., Ganz T., Leitman S.F., Fucharoen S., Miller J.L. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin // Nat. Med. 2007; 13 (9): 1096–1101. DOI: 10.1038/nm1629.
45. Tanno T., Porayette P., Sripichai O., Noh S.J., Byrnes C., Bhupatiraju A., Lee Y.T., Goodnough J.B., Harandi O., Ganz T., Paulson R.F., Miller J.L. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells // Blood. 2009; 114 (1): 181–186. DOI: 10.1182/blood-2008-12-195503.
46. Keela S.B., Dotya R., Liub L., Nemethc E., Cheriand S., Ganzc T., Abkowitz J.L. Evidence that the expression of transferrin receptor 1 on erythroid marrow cells mediates hepcidin suppression in the liver // Exp. Hematol. 2015; 43 (6): 469–748. DOI: 10.1016/j.exphem.2015.03.001.
47. Gao G., Liu S.Y., Wang H.J., Zhang T.W., Yu P., Duan X.L., Zhao S.E., Chang Y.Z. Effects of Pregnancy and Lactation on Iron Metabolism in Rats // BioMed Research International. 2015; 105325.
48. Peyssonnaux C., Zinkernagel A.S., Schuepbach R.A., Rankin E., Vaulont S., Haase V.H., Nizet V., Johnson R.S. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs) // J. Clin. Invest. 2007; 117 (7): 1926–1932. DOI: 10.1172/JCI31370.
49. Silvestri L., Pagani A., Camaschella C. Furinmediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis // Blood. 2008; 111 (2): 924–931.
50. Lakhal S., Schodel J., Townsend A.R., Pugh C.W., Ratcliffe P.J., Mole D.R. Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: new link between hypoxia signaling and iron homeostasis // J. Biol. Chem. 2011; 286 (6): 4090–4097. DOI: 10.1074/jbc.M110.173096.
51. Mastrogiannaki M., Matak P., Mathieu J.R., Delga S., Mayeux P.,Vaulont,S., Peyssonnaux C. Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis // Haematologica. 2012; 97 (6): 827–834. DOI: 10.3324/haematol.2011.056119.
52. Verga Falzacappa M.V., Vujic Spasic M., Kessler R., Stolte J., Hentze M.W., Muckenthaler M.U. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation // Blood. 2007; 109 (1): 353–358. DOI: 10.1182/blood-2006-07-033969.
53. Pietrangelo A., Dierssen U., Valli L., Garuti C., Rump A., Corradini E., Ernst M., Klein C., Trautwein C. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo // Gastroenterology. 2007; 132 (1): 294–300. DOI: 10.1053/j.gastro.2006.10.018.
54. Yu H., Lee H., Herrmann A., Buettner R., Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions // Nat. Rev. Cancer. 2014; 14 (11): 736–746. DOI: 10.1038/nrc3818.
55. Nemeth E., Valore E.V., Territo M., Schiller G., Lichtenstein A., Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein // Blood. 2003; 101 (7): 2461–2463. DOI: 10.1182/blood-2002-10-3235.
56. Nairz M., Haschka D., Demetz E., Weiss G. Iron at the interface of immunity and infection // Front Pharmacol. 2014; 5 (152): 00152. DOI: 10.3389/fphar.2014.00152.
57. Nemeth E., Ganz T. Anemia of inflammation // Hematol. Oncol. Clin. North. Am. 2014; 28 (4): 671–781. DOI: 10.1016/j.hoc.2014.04.005.
58. Bekri S., Gual P., Anty R., Luciani N., Dahman M., Ramesh B., Iannelli A., Staccini-Myx A., Casanova D., Ben Amor I., Saint-Paul M.C., Huet P.M. Sadoul J.L., Gugenheim J., Srai S.K., Tran A., Le Marchand-Brustel Y. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH // Gastroenterology. 2006; 131 (3): 788–796. DOI: 10.1053/j.gastro.2006.07.007.
59. Coimbra S., Catarino C., Santos-Silva A. The role of adipocytes in the modulation of iron metabolism in obesity // Obes Rev. 2013; 14 (10): 771–779. DOI: 10.1111/obr.12057.
60. Vuppalanchi R., Troutt J.S., Konrad R.J., Ghabril M., Saxena R., Bell L.N., Kowdley K.V., Chalasani N. Serum hepcidin levels are associated with obesity but not liver disease // Obesity (Silver Spring). 2014; 22 (3): 836–841. DOI: 10.1002/oby.20403.
61. Chung B., Matak P., McKie A.T., Sharp P. Leptin increases the expression of the iron regulatory hormone hepcidin in HuH7 human hepatoma cells // J. Nutr. 2007; 137 (11): 2366–2370.
62. Gabrielsen J.S., Gao Y., Simcox J.A., Huang J., Thorup D., Jones D., Cooksey R.C., Gabrielsen D., Adams T.D., Hunt S.C., Hopkins P.N., Cefalu W.T., McClain D.A. Adipocyte iron regulates adiponectin and insulin sensitivity // J. Clin. Invest. 2012; 122 (10): 3529–3540. DOI: 10.1172/JCI44421.
63. Besson-Fournier C., Latour C., Kautz L., Bertrand J., Ganz T., Roth M.P., Coppin H. Induction of activin B by inflammatory stimuli up-regulates expression of the ironregulatory peptide hepcidin through Smad1/5/8 signaling // Blood. 2012; 120 (2): 431–439. DOI: 10.1182/blood-2012-02-411470.
64. Meli R., Mattace Raso G., Irace C., Simeoli R., Di Pascale A., Paciello O., Pagano T.B., Calignano A., Colonna A., Santamaria R. High fat diet induces liver steatosis and early dysregulation of iron metabolismin rats // PLoS One. 2013; 8 (6): e66570. DOI: 10.1371/journal.pone.0066570.
65. Blindar’ V.N., Zubrikhina G.N., Matveyeva I.I. Аnemicheskiy sindrom i osnovnyye metabolity ferrokinetiki (ferritin, rastvorimyy retseptor transferrina, progepsidin, gepsidin-25 i endogennyy eritropoetin) [Anemic syndrome and major metabolites ferrokinetiki (ferritin, soluble transferrin receptor progepsidin, hepcidin-25 and endogenous erythropoietin)] // Meditsinskiy alfavit – Medical Alphabet. 2015; 2 (8): 16–19 (in Russian).
66. Jayaranee S., Sthaneshwar P., Sokkalingam S.https://www.ncbi.nlm.nih.gov/pubmed/18972320 Serum prohepcidin concentrations in rheumatoid arthritis // Pathology. 2009; 41 (2): 178–182. DOI: 10.1080/00313020802436840
67. Galushko E.А., Belen’kiy D.А., Аleksandrova E.N., Kashnikova L.N. Rol’ gepsidina v razvitii anemii u bol’nykh revmatoidnym artritom [The role of hepcidin in the development of anemia in patients with rheumatoid arthritis] // Nauchno-prakticheskaya revmatologiya – Rheumatology Science and Practice. 2012; 52 (3): 19–24 (in Russian).
68. Swellam M., Gabal K.M., Youssef S.S. Interleukin-1 receptor antagonist gene polymorphism and hepcidin in rheumatoid arthritis: Correlations with clinical and laboratory indices of disease activity // IUBMB Life. 2013; 65 (10): 883–888. DOI: 10.1002/iub.1205
69. Galushko E.А. Klinicheskoye znacheniye opredeleniya gepsidina pri anemii u bol’nykh revmatoidnym artritom [The clinical significance of determination of hepcidin in anemia in patients with rheumatoid arthritis] // Klinicheskaya meditsina – Clinical Medicine. 2014; 92 (6): 21–27 (in Russian).
70. Drozdov V.N., Lishchinskaya А.А., Parfenov А.I., Noskova K.K., Ruchkina I.N., Varvanina G.G., Tkachenko E.V. Kliniko-patogeneticheskiye varianty anemii u bol’nykh s vospalitel’nymi zabolevaniyami kishechnika [Clinico-pathogenetic variants of anemia in patients with inflammatory bowel disease] // Terapevticheskiy arkhiv – Therapeutic archive. 2012; 84 (2): 36–41 (in Russian).
71. Kaitha S., Bashir M., Ali T. Iron deficiency anemia in inflammatory bowel disease // World J Gastrointest Pathophysiol. 2015; 6 (3): 62–72. DOI: 10.4291/wjgp.v6.i3.62
72. Cherry J.D., Olschowka J.A., O’Banion M.K. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed // J. Neuroinflammation. 2014; 11 (98). DOI: 10.1186/1742-2094-11-98.
73. McCarthy R.C., Kosman D.J. Mechanisms and regulation of iron trafficking across the capillary endothelial cells of the blood-brain barrier // Frontiers in Molecular Neuroscience. 2015; 8 (31). DOI: 10.3389/fnmol.2015.00031.
74. Makeshova А.B., Levina А.А., Mamukova YU.I., Savchenko V.G.Regulyatornyye mekhanizmy obmena zheleza u bol’nykh ostrymi leykozami [The regulatory mechanisms of iron metabolism in patients with acute leukemia] // Terapevticheskiy arkhiv – Therapeutic archive. 2009; 81 (7): 16–20 (in Russian).
75. Tarasova N.E., Teplyakova E.D., SHestopalov А.V., Savis’ko А.А., Аslanyan K.S. Osobennosti metabolizma zheleza u detey s ostrym limfoblastnym leykozom [Features of iron metabolism in children with acute lymphoblastic leukemia] // Sovremennyye problemy nauki i obrazovaniya – Modern problems of science and education. 2012; 1: 31 (in Russian).
76. Maccio A., Madeddu C., Gramignano G., Mulas C., Tanca L., Cherchi M.C., Floris C., Omoto I., Barracca A., Ganz T. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study // Haematologica. 2015; 100 (1): 124–132. DOI: 10.3324/haematol.2014.112813.
77. Bordini J., Bertilaccio M.T., Ponzoni M., Fermo I.,Chesi M., Bergsagel P.L., Camaschella C., Campanella A. Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma // Haematologica. 2015; 100 (6): 834–841. DOI: 10.3324/haematol.2014.118000
78. Girelli D., Nemeth E., Swinkels D.W. Hepcidin in the diagnosis of iron disorders // Blood. 2016; 127 (23): 2809–1283. DOI: 10.1182/blood-2015-12-639112
79. Аndreichev N.А., Baleyeva L.V. Аnemiya khronicheskikh zabolevaniy [Anemia of chronic disease] // Rossiyskiy meditsinskiy zhurnal – Medical Journal of the Russian Federation. 2014; 2: 50–55 (in Russian).
80. Babitt J.L., Huang F.W., Xia Y., Sidis Y., Andrews N.C., Lin H.Y. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance // J. Clin. Invest. 2007; 117 (7): 1933–1939. DOI:10.1172/JCI31342.
81. Yu P.B., Hong C.C., Sachidanandan C., Babitt J.L., Deng D.Y., Hoyng S.A., Lin H.Y., Bloch K.D., Peterson R.T. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism // Nat. Chem. Biol. 2008; 4 (1): 33–41. DOI: 10.1038/nchembio.2007.54.
82. Pinto J.P., Ribeiro S., Pontes H., Thowfeequ S., Tosh D., Carvalho F., Porto G. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha // Blood. 2008; 111 (12): 5727–5733. DOI: 10.1182/blood-2007-08-106195.
83. Sasu B.J., Cooke K.S., Arvedson T.L., Plewa C., Ellison A.R., Sheng J., Winters A., Juan T., Li H., Begley C.G., Molineux G. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia // Blood. 2010; 115 (17): 3616–3624. DOI: 10.1182/blood-2009-09-245977.
84. Canavesi E., Alfieri C., Pelusi S., Valenti L. Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease? // World J Nephrol. 2012; 1 (6): 166–176. DOI: 10.5527/wjn.v1.i6.166.
85. Sebastiani G., Wilkinson N., Pantopoulos K. Pharmacological Targeting of the Hepcidin/Ferroportin Axis // Front Pharmacol. 2016; 7: 160. DOI: 10.3389/fphar.2016.00160.
Review
For citations:
Prokhorenko T.S., Zima A.P., Saprina T.V., Musina N.N., Shakhmanova N.S., Novitsky V.V. Differential diagnosis of anemia in pregnant women. Bulletin of Siberian Medicine. 2017;16(1):140-151. (In Russ.) https://doi.org/10.20538/1682-0363-2017-1-140-151
Views:
5312
Email this article 